Stem Cell Therapeutics Corp. Announces Enrollment of First Patient in the modified REGENESIS Phase IIb Stroke Trial
August 11 2009 - 9:48AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:
SSS) is pleased to announce the enrollment of the first patient in
its modified REGENESIS Phase IIb acute ischemic stroke trial. The
modified REGENESIS trial is a double-blind, randomized,
placebo-controlled Phase IIb clinical trial for SCT's lead program,
NTx®-265, for the treatment of acute ischemic stroke. This first
patient was enrolled by the clinical team of Dr. Vijaya
Pamidimukkala from the Lalitha Super Specialties Hospital Pvt Ltd
in Guntur, Hyderabad, A.P. Co-lead investigators for the modified
REGENESIS Phase IIb trial are Dr. Steven C. Cramer of the
University of California, Irvine, and Dr. Michael D. Hill of the
Foothills Hospital at the University of Calgary.
Dr. Alan Moore, President and CEO, commented as follows:
"We are very happy to have begun recruiting the modified Phase
IIb REGENESIS stroke trial. We have great expectations that this
Phase IIb acute ischemic stroke trial will continue to build upon
the positive clinical data available to-date, specifically the
exciting results highlighted by the meta-analysis as announced on
July 27th. Trial completion for the modified Phase IIb clinical
stroke trial is anticipated for the end of calendar year 2009,
allowing top-line data to be available by the end of Q1 09."
The modified REGENESIS Phase IIb acute ischemic stroke trial
will be a multi-site trial, projected to enroll 128 patients at
sites located in India, Canada and the U.S.
Additionally, the early warrant exercise incentive program which
was announced on July 8th has since closed and is no longer
available.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The
Company's extensive patent portfolio of owned and licensed
intellectual property supports the potential expansion into future
clinical programs in numerous neurological diseases such as
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024